 Focused on treating rare epilepsies and neuropsychiatric disorders Lead candidate Zygel targeted at multiple conditions RECONNECT trial with Zygel for Fragile X syndrome in 3Q 2021 What Zynerba does: Zynerba Pharmaceuticals Inc NASDAQ:ZYNE is doing trailblazing work pushing clinical trials for cannabis-derived treatments. The specialty pharma company is developing novel transdermal CBD treatments for patients suffering rare epilepsies and neurological disorders. 